Department of Radiation Oncology, St Jude Children's Research Hospital, Memphis, TN.
Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins Medicine, Baltimore, MD.
J Clin Oncol. 2022 Jan 1;40(1):83-95. doi: 10.1200/JCO.21.01480. Epub 2021 Oct 29.
To characterize the association between neurocognitive outcomes (memory and processing speed) and radiation (RT) dose to the hippocampus, corpus callosum (CC), and frontal white matter (WM) in children with medulloblastoma treated on a prospective study, SJMB03.
Patients age 3-21 years with medulloblastoma were treated at a single institution on a phase III study. The craniospinal RT dose was 23.4 Gy for average-risk patients and 36-39.6 Gy for high-risk patients. The boost dose was 55.8 Gy to the tumor bed. Patients underwent cognitive testing at baseline and once yearly for 5 years. Performance on tests of memory (associative memory and working memory) and processing speed (composite processing speed and perceptual speed) was analyzed. Mixed-effects models were used to estimate longitudinal trends in neurocognitive outcomes. Reliable change index and logistic regression were used to define clinically meaningful neurocognitive decline and identify variables associated with decline.
One hundred and twenty-four patients were eligible for inclusion, with a median neurocognitive follow-up of 5 years. Mean right and left hippocampal doses were significantly associated with decline in associative memory in patients without posterior fossa syndrome (all < .05). Mean CC and frontal WM doses were significantly associated with decline in both measures of processing speed (all < .05). Median brain substructure dose-volume histograms were shifted to the right for patients with a decline in associative memory or processing speed. The odds of decline in associative memory and composite processing speed increased by 23%-26% and by 10%-15% for every 1-Gy increase in mean hippocampal dose and mean CC or frontal WM dose, respectively.
Increasing RT dose to the CC or frontal WM and hippocampus is associated with worse performance on tests of processing speed and associative memory, respectively. Brain substructure-informed RT planning may mitigate neurocognitive impairment.
描述神经认知结果(记忆和处理速度)与接受前瞻性研究(SJMB03)治疗的髓母细胞瘤患儿海马体、胼胝体(CC)和额白质(WM)的放射治疗(RT)剂量之间的关系。
在一个单机构的 III 期研究中,对年龄在 3-21 岁的髓母细胞瘤患者进行治疗。平均风险患者的颅脊髓 RT 剂量为 23.4Gy,高危患者为 36-39.6Gy。肿瘤床给予 55.8Gy 的剂量增强。患者在基线和每年一次接受认知测试,共进行 5 年。分析了记忆(联想记忆和工作记忆)和处理速度(综合处理速度和知觉速度)测试的表现。采用混合效应模型估计神经认知结果的纵向趋势。可靠变化指数和逻辑回归用于定义有临床意义的神经认知下降,并确定与下降相关的变量。
共有 124 名患者符合纳入标准,神经认知随访中位数为 5 年。在没有后颅窝综合征的患者中,右和左海马体的平均剂量与联想记忆的下降显著相关(均 <.05)。CC 和额 WM 的平均剂量与两种处理速度测量值的下降均显著相关(均 <.05)。对于联想记忆或处理速度下降的患者,中位数脑亚结构剂量-体积直方图向右移位。平均海马体剂量和 CC 或额 WM 剂量每增加 1Gy,联想记忆和综合处理速度下降的几率分别增加 23%-26%和 10%-15%。
CC 或额 WM 和海马体的 RT 剂量增加与处理速度和联想记忆测试的表现下降相关。基于脑亚结构的 RT 计划可能减轻神经认知损伤。